GRAIL is a healthcare company applying next-generation sequencing, population-scale clinical studies, and machine learning to detect multiple deadly cancer types at earlier, more curable stages. Founded in 2016, the company operates at the intersection of genomic medicine, computational biology, and clinical research, maintaining facilities in Menlo Park, California; Washington, D.C.; North Carolina; and the United Kingdom.
The company's principal product, Galleri, is a multi-cancer early detection blood test capable of identifying over 50 types of cancer - including more than 45 that lack recommended screening tests today - through a single blood draw. GRAIL runs one of the largest clinical study programs in genomic medicine and collaborates with health systems, academic medical centers, and pharmaceutical companies worldwide.
GRAIL's technical work spans next-generation sequencing, software engineering, automation, and machine learning. The organization is multi-disciplinary by design, bringing together scientists, engineers, and physicians to address a defining challenge in oncology.
